Nate Edwards of Arya Consulting moderates a discussion with Elisabeth Gardiner of Tevard Biosciences and Donny Xu of the RTW Institute about the regulatory and manufacturing hurdles facing rare disease drug developers.
|Articles|December 2, 2016
- Pharmaceutical Technology-12-02-2016
- Volume 40
- Issue 12
Automated Microscope for Multimodal Imaging
Zeiss’s Axio Observer inverted microscope platform includes new automation features, allowing researchers to perform multimodal imaging of living and fixed specimens.
Zeiss’s Axio Observer inverted microscope platform includes new automation features, allowing researchers to perform multimodal imaging of living and fixed specimens. Among these features is Autocorr, a technology that allows adaption of immersion objectives to varying sample carriers and imaging conditions. The correction of spherical aberrations results in improved image contrast, higher resolution, and more efficient fluorescence detection.
The microscope includes a new autoimmersion option that builds up and maintains stable water immersion without evaporation or air bubbles, and is compatible with multiple water immersion objectives in the nosepiece. The Axio Observer includes interfaces for imaging technologies, ranging from widefield transmitted light to 3D sectioning, fast and sensitive confocal super-resolution imaging, and structured illumination as well as photoactivated localization microscopy.
Articles in this issue
almost 10 years ago
Options in Employee Trainingalmost 10 years ago
Biosimilars Supporting Contract Manufacturers’ Growthalmost 10 years ago
Airlocks for cGMP Facilitiesalmost 10 years ago
Evaluating Mixing in a Single-Use Bioprocessing Systemalmost 10 years ago
Shrink Banders for Labeling Applicationsalmost 10 years ago
Chromatograph Enables Fast Recovery of Target Compoundsalmost 10 years ago
From Bitter to Sweet: Developing a User-Friendly Painkilleralmost 10 years ago
Nurturing the Relationship Between Industry and Regulatorsalmost 10 years ago
Getting involved with pharma standardsalmost 10 years ago
Industry’s role in helping to create standardsRelated to this article
FDA grants ravulizumab accelerated approval in IgA nephropathy after a 43.4% proteinuria cut, signaling new IV biologic demand for drug manufacturers.
Jane Zhang of ETCH Sourcing explains why geopolitics, transparency, and partnership now weigh as heavily as cost and quality when companies choose suppliers, in this episode of Ask the Expert, moderated by Susan J. Schniepp of Nelson Labs.
FDA approves GSK's bepirovirsen for chronic hepatitis B after a 19% functional cure rate, raising oligonucleotide scale-up stakes for manufacturers.
Ravi Kiran Kaja, PhD, USP, explains what harmonization of extractables and leachables standards looks like in practice.
Jaenisch, Muraru, and Pandey discuss new skills for QC and regulatory teams, plus patient trust, as new approach methodologies reshape pharma.
Nine duloxetine recalls since 2024 show why generic drug manufacturers need route-level nitrosamine risk assessment, not end-product testing alone.
OpenAI acquired Orchestra Bio to pair AI agents that track drug development timelines with its Rosalind life sciences tools, raising oversight questions for pharma teams.
Trending on Pharmaceutical Technology
1
OpenAI Bets on Accelerating Drug Development Timelines With Orchestra Bio
2
AAPS PharmSci 360 2026: System Suitability Standards in E&L Testing
3
Nitrosamine Problems and Industry Solutions: PharmTech Explained
4
FDA Approves Bepirovirsen: Why Oligonucleotide CDMOs Should Take Note
5